Stock Scorecard
Stock Summary for Trevena Inc (TRVN) - $4.13 as of 9/6/2024 3:11:19 PM EST
Total Score
9 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TRVN
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TRVN
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TRVN
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for TRVN
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for TRVN
Financial Details for TRVN
Company Overview |
|
---|---|
Ticker | TRVN |
Company Name | Trevena Inc |
Country | USA |
Description | Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of new drugs for patients affected by disorders of the central nervous system. The company is headquartered in Chesterbrook, Pennsylvania. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 6/30/2024 |
Next Earnings Date | 11/12/2024 |
Stock Price History |
|
Last Day Price | 4.13 |
Last Day Price Updated | 9/6/2024 3:11:19 PM EST |
Last Day Volume | 12,460 |
Average Daily Volume | 162,982 |
52-Week High | 20.00 |
52-Week Low | 3.35 |
Last Price to 52 Week Low | 23.28% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 34.82 |
Sector PE | 80.12 |
5-Year Average PE | -56.24 |
Free Cash Flow Ratio | 0.22 |
Industry Free Cash Flow Ratio | 13.19 |
Sector Free Cash Flow Ratio | 30.42 |
Current Ratio Most Recent Quarter | 3.46 |
Total Cash Per Share | 19.19 |
Book Value Per Share Most Recent Quarter | -22.23 |
Price to Book Ratio | 0.36 |
Industry Price to Book Ratio | 6.02 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 7.95 |
Industry Price to Sales Ratio Twelve Trailing Months | 7.56 |
Sector Price to Sales Ratio Twelve Trailing Months | 6.66 |
Share Statistics |
|
Total Shares Outstanding | 852,930 |
Market Capitalization | 3,522,601 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 24.97% |
Reported EPS 12 Trailing Months | -54.58 |
Reported EPS Past Year | -6.11 |
Reported EPS Prior Year | -3.13 |
Net Income Twelve Trailing Months | -36,988,000 |
Net Income Past Year | -40,289,000 |
Net Income Prior Year | -53,700,000 |
Quarterly Revenue Growth YOY | -89.20% |
5-Year Revenue Growth | -2.83% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 16,367,000 |
Total Cash Past Year | 32,975,000 |
Total Cash Prior Year | 38,320,000 |
Net Cash Position Most Recent Quarter | -15,160,000 |
Net Cash Position Past Year | 2,166,000 |
Long Term Debt Past Year | 30,809,000 |
Long Term Debt Prior Year | 13,430,000 |
Total Debt Most Recent Quarter | 31,527,000 |
Equity to Debt Ratio Past Year | -0.33 |
Equity to Debt Ratio Most Recent Quarter | -1.51 |
Total Stockholder Equity Past Year | -7,657,000 |
Total Stockholder Equity Prior Year | 15,599,000 |
Total Stockholder Equity Most Recent Quarter | -18,957,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -31,556,000 |
Free Cash Flow Per Share Twelve Trailing Months | -37.00 |
Free Cash Flow Past Year | -33,076,000 |
Free Cash Flow Prior Year | -51,505,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.37 |
MACD Signal | -0.41 |
20-Day Bollinger Lower Band | 2.04 |
20-Day Bollinger Middle Band | 7.07 |
20-Day Bollinger Upper Band | 12.10 |
Beta | 1.02 |
RSI | 39.41 |
50-Day SMA | 11.64 |
150-Day SMA | 113.24 |
200-Day SMA | 374.88 |
System |
|
Modified | 9/7/2024 3:19:54 PM EST |